Stemline Therapeutics, Inc. (NASDAQ: STML) Starts Presentation at 30th Annual ROTH Conference
Stemline Therapeutics (NASDAQ: STML) is a clinical-stage biopharmaceutical company engaged in the development of novel oncology therapeutics. The company is currently developing three clinical-stage product candidates: SL-401, SL-801 and SL-701. Stemline’s preclinical pipeline includes two next-generation IL-3R-targeted compounds: SL-501 and SL-101. The company has additionally constructed an innovative drug discovery platform called StemScreen™ and has built an extensive intellectual property portfolio that includes some of the earliest patents in the CSC field. For more information, visit the company’s website at www.stemline.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network…







